Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Nov 1;17(1):1019–1029. doi: 10.3892/ol.2018.9656

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Wdowiak et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 4. — Galectin serum levels and clinical status in patients with CLL prior to and following chemotherapeutic treatment. Concentration of (A) galectin-1, (B) galectin-9, (C) galectin-3 and (D) galectin 3-binding protein in patients with CLL at Binet stage A, B or C. Data are presented as the mean ± standard error of the mean. Binet A (n=14), Binet B (n=15) and Binet C (n=19). Data were analyzed using one-way analysis of variance followed by Dunnett's multiple comparison post-hoc test. *P<0.05 for Binet C or **P<0.001 for Binet B when compared with Binet A, respectively, prior to CTH. *P<0.05 for Binet B when compared with Binet A, following 6 months. CLL, chronic lymphocytic leukemia.